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Methods: This is a cross-sectional study of a consecutive co- 
hort of 110 patients with OA of the knee unresponsive to anti- 
inflammatory therapy who underwent arthroscopic debridement. 
The mean follow-up time was 34 months (range 24-74 months). 
The cohort consisted of 36 males and 74 females with an aver- 
age age of 61.7 years. Pain was assessed with the pain domain 
of the Knee Society scoring system. X-rays were scored by the 
Kellgren-Lawrence method, and limb alignment and medial and 
lateral joint space widths were measured. The severity of car- 
tilage lesions was scored intraoperatively by a modified Noyes 
grading system. Following grading, a standardized surgical de- 
bridement of damaged cartilage was performed. 
Results: Overall, 72/110 (65%) of patients had substantial pain 
relief post-operatively. The severity of pre-operative pain and the 
type of symptoms had no influence on postoperative pain scores. 
The severity of OA, as measured by the Kellgren-Lawrence score 
had a profound effect on outcome. 84% of knees with minimal 
radiographic hanges (grade 2) had substantial pain relief post- 
operatively, while only 25% of knees with severe OA (grade 4) 
experienced adequate pain relief. Of knees with moderate OA 
(grade 3) about one half (53%) experienced pain relief while an 
equal number were treatment failures. 85% of knees with a nor- 
mal tibiofemoral angle were considered treatment successes. A 
joint space width of 2mm or less was associated with poorer post- 
operative pain scores and a higher likelihood of treatment failure 
compared to knees with a joint space 3mm or greater. Lesion 
severity was also highly predictive of clinical outcome. 
Conclusions: A consensus on the usefulness of arthroscopy for 
OA of the knee has been elusive for 20 years. Most studies have 
aggregated outcome scores without regard to the extent of arthri- 
tis. We performed subgroup analysis to identify the knee char- 
acteristics, if any, that predicted symptomatic improvement. Our 
data revealed radiographic subsets of the population of knees 
with OA that can be associated with outcome after arthroscopic 
debridement. Still unresolved is the role of arthroscopy in the rel- 
atively large population of patients with moderate OA (Kellgren- 
Lawrence grade 3). For this group, cartilage lesion severity mea- 
sured intraoperatively was the only indicator of clinical outcome. 
Patients need to be counseled that their clinical outcome may 
depend upon the severity of cartilage lesions determined at 
surgery and their expectations of benefit need to take this into 
account. 
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To investigate parallel effects of a novel oral form of salmon cal- 
citonin (sCT) on bone resorption and cartilage degradation in el- 
derly women, and associations between rate of cartilage degra- 
dation, surrogate markers of osteoarthritis, and responsiveness 
to the pharmacodynamic effects of sCT. 
This was a randomized, double-blind, placebo-controlled clinical 
trial including 152 postmenopausal women. Participants received 
either sCT (0.15, 0.4, 1.0, 2.5 mg) combined with an Eligen ® 
technology-based carrier molecule (CNAC, 200 mg), or placebo 
for 3 months. The efficacy parameters were the changes in the 
24-hour urinary excretion of the C-telopeptide of collagen type II 
(CTX II; marker of cartilage degradation) and the C-telopeptide 
of collagen type I (CTX I; marker of bone resorption) from base- 
line at Month 3. Values were corrected for creatinine excretion. 
Personal interview collected information on joint symptoms, used 
medications, or joint replacements related to osteoarthritis. 
There were no differences between the different intervention 
groups in terms of age, BMI, and baseline measures of CTX I 
and II. At baseline, there was a weak correlation between mea- 
sures of CTX I and CTX II (R2=0.17, p<0.05), sCT induced dose- 
dependent decreases in the 24-hour urinary excretion of CTX 
II (p=0.002). Compared with baseline values, the inhibition was 
significant at the 0.4 mg dose and reached maximum at the 1.0 
mg dose (-19.7%, p=0.009). Similar pattern of changes was seen 
with CTX I. The maximal inhibition of CTX I excretion was seen 
at the 1.0 mg dose (-41.0%, p<0.001). There was a significant 
association between the 3-month changes in CTX I and CTX II 
(R2=0.33, p<0.001). In this population, 27% of women reported 
diagnosed OA or chronic joint pain. Women ih the highest CTX 
II tertile (3904-17 ng/mmol) reported joint symptoms and history 
of osteoarthroplasty more frequently compared with women in 
the lowest tertile (p<0.05). Furthermore, there were generally 
more pronounced decreases in CTX II to sCT in women belong- 
ing to the highest tertile of baseline CTX II. When focusing on 
subjects with high cartilage turnover at baseline, women who re- 
ceived treatment with 1.0 mg sCT showed statistically significant 
decreases compared with the effects of placebo (-30.6%, 95% 
CI -55.5 to -5.7%, p=0.01). 
The parallel decreases in CTX I and CTX II levels to sCT suggest 
that inhibition of bone turnover may confer favourable effects on 
cartilage turnover, but does not exclude the possibility of direct 
effects of sCT on chondrocytes. Based on these potential chon- 
droprotective ffects and the well-documented analgesic effects 
of calcitonin, further clinical assessment of this novel oral formula- 
tion as a candidate drug for the prevention of osteoarthritis eems 
warranted. 
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Objective: 1. To prove the efficacy over pain and function of 
Sodium hyaluronate and Chondroitin sulfate (HS/CS), blended in 
a gel, applied intraarticularly, vs. a Hylan G F 20 gel applied in- 
traarticularly, in the treatment of Osteoarthritis of the knee. 
2. To analyze the functional results using the proposed treatment. 
3. To determine the efficacy of the treatment using a visual analog 
scale (WOMAC). 
4. To report the final results. 
The trial used a group of 20 persons, 13 women and 7 men 
with ostheoarthritis grade II in the knee or patellar chondromala- 
sin. Men's age was 474-23.23 years (16 minimum, 80 maximum). 
Women's age was 60.54-16.02 years(30 minimum, 87 maximum). 
10 of them were treated with HS/CS and 10 with H G-F 20. They 
were evaluated at the beginning with Womac-index and with x- 
rays. They will be assigned to a treatment group to one of the 
following dosing regimens: a blend of 30 mg sodium hyaluronate 
and 40mg. chondroitin sodium sulfate/c.c. 1.5 c.c. every 15 days 
for 3 applications, 1.5 c.c. 90 days later and 1.5 c.c. 180 days af- 
ter that, or high molecular weight Hyaluronic Acid Hylane GF 20, 
8 mg./c.c. 2. c.c. every 8 days (3 applications) 2 c.c. 90 days later 
and 2 c.c. 180 days afterwards; both by intraarticular application 
at the knee, after aspiration of the existing synovial fluid and with 
an aseptic technique. 
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Duration of the trial: 12 months, with monthly assessments, re- 
gardless of the day of application to each patient. 
Of the 20 patients, only 2 had a diagnosis of Chondromalasia, the 
others had Osteoarthritis G-II. 
Results: The assessment of the two treatment groups was eval- 
uated by the WOMAC scale in 4 categories: Poor, Fair, Good and 
Excellent. The difference for both treatment groups was statisti- 
cally significant (p=0.021). 
Pain in the evolution of the treated patients was evaluated using 
a scale of four categories: No Pain, Occasional Pain, Moderate 
Pain and Intense Pain. 40% of the patients in the HS/CS group 
had occasional, moderate or intense pain. While 90% of those 
who received Hylan GF-20 had occasional, moderate or intense 
pain. 
The evolution of the patients was evaluated by presence or ab- 
sence of crepitation in the treated joint. In this regard, the differ- 
ence between treatment groups was very significant (p=0.002), 
with presence of crepitation in 82% of the patients in the Hylan 
GF-20 group versus 18% of patients with crepitation in the HS/CS 
group. 
Any adverse event in each group. 
Conclusion: Definitely the evolution of the sintomatology and the 
function was better for the group treated with Sodium Hyaluronate 
and Chondroitin sulfate than for Hylan-GF 20. Although the begin- 
ning was similar for both in terms of controlling the pain, as the 
trial continued and time passed, the HS/CS group kept a stable 
improvement in this matter and in the function until the end of the 
trial. 
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Background: The benefits of arthroscopy for the treatment of os- 
teoarthritis of the knee have recently been questioned. Although 
joint replacement has successful results, many patients are seek- 
ing an alternative treatment to delay replacement. 
Type of Study: Case series 
Hypothesis/Purpose: The purpose of this study was to evalu- 
ate the functional and subjective outcomes of patients with se- 
vere osteoarthritis of the knee that underwent a comprehensive 
arthroscopic treatment regimen. 
Methods: Between August 2000 and November 2001, 69 
knees in 61 patients were treated with a comprehensive arthro- 
scopic regimen. Inclusion criteria included severe osteoarthritis 
(Kellgren-Lawrence score of 3 or 4) and minimum 2 year follow- 
up. Arthroscopic treatment included joint insufflation, lysis of ad- 
hesions, anterior interval release, contouring of cartilage defects 
and meniscus tears to a stable rim, synovectomy, removal of 
loose bodies, and removal of osteophytes that affected termi- 
nal extension. Exclusion criteria included treatment of chondral 
defects with microfracture. Failure of the arthroscopic protocol 
was defined as knees requiring arthroplasty. Preoperative radio- 
graphic analysis included joint space width, hip/knee angle, and 
shift in weight bearing axis measurements. The shift in the weight 
bearing axis was calculated as the ratio of the distance between 
the center of the knee joint to the point the axis intersected the 
knee and the width of the compartment through which the axis 
crossed. 
Results: The average patient age was 57 (range 37 to 78), with 
35 males and 26 females. Patients had an average of 1.5 previ- 
ous surgeries (range 0 to 12). The average pre-operative Lysholm 
score was 49 (range 14 to 79). On average, knees were insuf- 
flated with 170cc of lactated ringer's solution (range 120 to 240). 
Nine knees failed, with a survivorship of 83% at 3 years. Aver- 
age follow-up was 31 months (range 24 to 41). Average Lysholm 
was 74 (range 37 to 100), with an average improvement of 25 
points. The average Tegner was 4 (range 0 to 8). Average patient 
satisfaction was 8 (range 1 to 10). Average WOMAC pain was 
4 (range 0 to 14), WOMAC stiffness was 2 (range 0 to 4), and 
WOMAC function was 11 (range 0 to 44). Independent predictors 
of improvement in Lysholm score included shift in weight bearing 
axis and pre-operative Lysholm score. 
Conclusion: This comprehensive, arthroscopic treatment reg- 
imen can improve function and activity levels in patients with 
end stage osteoarthritis and, furthermore, can delay arthroplasty. 
Long term results are needed to determine how long arthroplasty 
can be delayed by treatment with this protocol. 
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Background: Osteoarthritis (OA) is the most prevalent ype of 
arthritis in the United States and is most common in the medial 
compartment of the knee. Many studies describe hallmark gait 
deviations in people with medial knee OA (MKOA) including re- 
duced knee flexion and greater knee adduction moments; how- 
ever, little emphasis has been placed on the associated muscle 
activation strategies used by these patients. Our previous work 
has shown that patients with MKOA use greater medial mus- 
cle co-activation during walking that may be a compensation for 
greater passive laxity that appears only on the medial side of 
the joint. Higher medial muscle co-contraction could exacerbate 
the progression of OA by further increasing contact forces in the 
diseased medial compartment. Recent work indicates that many 
people with MKOA report knee instability, described as the sen- 
sation of shifting, buckling or giving way in the knee. We hypothe- 
size that higher muscle co-activation may represent a strategy to 
reduce instability and that greater medial laxity may influence the 
instability thus eliciting more co-contraction among medial mus- 
cles. 
Aim of Study: The purpose of our study was to investigate the 
influences of self-reported knee instability on muscle activation 
strategies during a disturbed walking paradigm in which knee sta- 
bility is challenged. 
Methods: Five persons (39-72 yrs) with diagnosed MKOA (KL 
Grade II or greater) and five control subjects (38 - 71 yrs) with- 
out history of lower extremity problems participated. Sagittal and 
frontal plane joint angles and muscle activation data were col- 
lected simultaneously as each subject walked across a moveable 
platform for 20 walking trials. During 10 randomly distributed trials 
the platform translated laterally immediately following heel strike 
to challenge the stability of the joint. Muscle co-activation was de- 
termined for four muscle groups - lateral quadriceps/hamstrings 
(LQH), lateral quadriceps/gastrocnemius (LQG), medial quadri- 
ceps/hamstrings (MQH) and medial quadriceps/gastrocnemius 
(MQG). Self-reported knee instability (Knee Outcome Survey) 
was obtained from each subject. Analyses were performed and 
significance was set at p _<0.10. 
Results: Four of the five subjects with MKOA reported knee in- 
stability; 3 subjects reported that instability interferes with daily 
function. No control subjects reported instability. When stability 
was challenged, subjects with MKOA (OA) demonstrate greater 
knee flexion during midstance (p=0.016) and greater muscle co- 
contraction during the initial loading phase of gait as well as dur- 
ing midstance (p=0.019 - 0.10). 
